Metabolic dysfunction-associated steatotic liver disease (MASLD) is no longer viewed as an isolated hepatic condition but as a complex multisystem disorder. Dr. Sven Francque of Antwerp University Hospital emphasizes that the disease is driven by extrahepatic factors, particularly dysfunctional adipose tissue and inflammatory mediators. This pathophysiology creates significant patient heterogeneity, where genetic and environmental factors dictate vulnerability to metabolic stress beyond simple caloric overload.
Hepatologists are now adopting a holistic approach that addresses cardiovascular and metabolic consequences alongside liver health. Pharmacological strategies increasingly target the systemic metabolic milieu rather than intrahepatic mechanisms alone. However, significant diagnostic gaps persist. Current non-invasive tools struggle to identify critical tipping points toward decompensation or capture vascular alterations without biopsy. Clinicians must move beyond oversimplified cirrhosis classifications to better stratify risk in primary care settings.
Therapeutic landscapes are evolving toward individualized combination treatments. While single agents show efficacy, the complex nature of MASLD often requires targeting multiple pathophysiological pathways. Experts suggest optimizing cardiometabolic drivers first, adding liver-targeted therapies only if response is insufficient. Conversely, patients with advanced disease may require immediate combination regimens. Progress remains hindered by reimbursement challenges and the lack of validated short-term surrogate markers comparable to HbA1c in diabetes care.
At EASL 2026, global consensus efforts marked a turning point for clinical practice. Key developments included the Baveno VIII update on portal hypertension management and new definitions for acute-on-chronic liver failure. These harmonized guidelines aim to standardize research and improve patient outcomes worldwide. The medical community continues to combat misconceptions that mild steatosis is benign, recognizing instead that liver fat signals systemic metabolic ill health requiring proactive investigation.